Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
News|Articles|July 31, 2026
July 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
Author(s)Leah Kuntz
Check out the pipeline updates from July!
Advertisement
Advertisement
Take a look at this month’s developments in the psychiatric treatment pipeline. We compiled a recap of the latest news here, just in case you missed any of the updates.
Related to this article
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
Lipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression.
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement